PURPOSE: To characterize the impact of graft T-cell composition on outcomes of reduced-intensity conditioned (RIC) allogeneic hematopoietic stem-cell transplantation (alloHSCT) in adults with hematologic malignancies. PATIENTS AND METHODS: We evaluated associations between graft T-cell doses and outcomes in 200 patients who underwent RIC alloHSCT with a peripheral blood stem-cell graft. We then studied 21 alloHSCT donors to identify predictors of optimal graft T-cell content. RESULTS: Higher CD8 cell doses were associated with a lower risk for relapse (adjusted hazard ratio [aHR], 0.43; P = .009) and improved relapse-free survival (aHR, 0.50; P = .006) and overall survival (aHR, 0.57; P = .04) without a significant increase in graft-versus-host disease or nonrelapse mortality. A cutoff level of 0.72 × 10(8) CD8 cells per kilogram optimally segregated patients receiving CD8(hi) and CD8(lo) grafts with differing overall survival (P = .007). Donor age inversely correlated with graft CD8 dose. Consequently, older donors were unlikely to provide a CD8(hi) graft, whereas approximately half of younger donors provided CD8(hi) grafts. Compared with recipients of older sibling donor grafts (consistently containing CD8(lo) doses), survival was significantly better for recipients of younger unrelated donor grafts with CD8(hi) doses (P = .03), but not for recipients of younger unrelated donor CD8(lo) grafts (P = .28). In addition, graft CD8 content could be predicted by measuring the proportion of CD8 cells in a screening blood sample from stem-cell donors. CONCLUSION: Higher graft CD8 dose, which was restricted to young donors, predicted better survival in patients undergoing RIC alloHSCT.
PURPOSE: To characterize the impact of graft T-cell composition on outcomes of reduced-intensity conditioned (RIC) allogeneic hematopoietic stem-cell transplantation (alloHSCT) in adults with hematologic malignancies. PATIENTS AND METHODS: We evaluated associations between graft T-cell doses and outcomes in 200 patients who underwent RIC alloHSCT with a peripheral blood stem-cell graft. We then studied 21 alloHSCT donors to identify predictors of optimal graft T-cell content. RESULTS: Higher CD8 cell doses were associated with a lower risk for relapse (adjusted hazard ratio [aHR], 0.43; P = .009) and improved relapse-free survival (aHR, 0.50; P = .006) and overall survival (aHR, 0.57; P = .04) without a significant increase in graft-versus-host disease or nonrelapse mortality. A cutoff level of 0.72 × 10(8) CD8 cells per kilogram optimally segregated patients receiving CD8(hi) and CD8(lo) grafts with differing overall survival (P = .007). Donor age inversely correlated with graft CD8 dose. Consequently, older donors were unlikely to provide a CD8(hi) graft, whereas approximately half of younger donors provided CD8(hi) grafts. Compared with recipients of older sibling donor grafts (consistently containing CD8(lo) doses), survival was significantly better for recipients of younger unrelated donor grafts with CD8(hi) doses (P = .03), but not for recipients of younger unrelated donorCD8(lo) grafts (P = .28). In addition, graft CD8 content could be predicted by measuring the proportion of CD8 cells in a screening blood sample from stem-cell donors. CONCLUSION: Higher graft CD8 dose, which was restricted to young donors, predicted better survival in patients undergoing RIC alloHSCT.
Authors: J M Zaucha; T Gooley; W I Bensinger; S Heimfeld; T R Chauncey; R Zaucha; P J Martin; M E Flowers; J Storek; G Georges; R Storb; B Torok-Storb Journal: Blood Date: 2001-12-01 Impact factor: 22.113
Authors: Andrew R Rezvani; Barry E Storer; Katherine A Guthrie; H Gary Schoch; David G Maloney; Brenda M Sandmaier; Rainer Storb Journal: Biol Blood Marrow Transplant Date: 2014-09-30 Impact factor: 5.742
Authors: Edmund K Waller; Brent R Logan; Wayne A C Harris; Steven M Devine; David L Porter; Shin Mineishi; John M McCarty; Corina E Gonzalez; Thomas R Spitzer; Oleg I Krijanovski; Michael L Linenberger; Ann Woolfrey; Alan Howard; Juan Wu; Dennis L Confer; Claudio Anasetti Journal: J Clin Oncol Date: 2014-06-30 Impact factor: 44.544
Authors: C Kollman; C W Howe; C Anasetti; J H Antin; S M Davies; A H Filipovich; J Hegland; N Kamani; N A Kernan; R King; V Ratanatharathorn; D Weisdorf; D L Confer Journal: Blood Date: 2001-10-01 Impact factor: 22.113
Authors: Philippe Armand; Haesook T Kim; Brent R Logan; Zhiwei Wang; Edwin P Alyea; Matt E Kalaycio; Richard T Maziarz; Joseph H Antin; Robert J Soiffer; Daniel J Weisdorf; J Douglas Rizzo; Mary M Horowitz; Wael Saber Journal: Blood Date: 2014-04-17 Impact factor: 22.113
Authors: Loren Gragert; Mary Eapen; Eric Williams; John Freeman; Stephen Spellman; Robert Baitty; Robert Hartzman; J Douglas Rizzo; Mary Horowitz; Dennis Confer; Martin Maiers Journal: N Engl J Med Date: 2014-07-24 Impact factor: 91.245
Authors: Yi-Bin Chen; Erin Coughlin; Kevin F Kennedy; Edwin P Alyea; Philippe Armand; Eyal C Attar; Karen K Ballen; Corey Cutler; Bimalangshu R Dey; John Koreth; Steven L McAfee; Thomas R Spitzer; Joseph H Antin; Robert J Soiffer; Vincent T Ho Journal: Biol Blood Marrow Transplant Date: 2013-04-02 Impact factor: 5.742
Authors: Lisa M Crisalli; Joanne T Hinkle; Christopher C Walling; Mary Sell; Noelle V Frey; Elizabeth O Hexner; Alison W Loren; Selina M Luger; Edward A Stadtmauer; David L Porter; Ran Reshef Journal: Biol Blood Marrow Transplant Date: 2018-02-02 Impact factor: 5.742
Authors: Yi-Bin Chen; Jennifer Le-Rademacher; Ruta Brazauskas; Deidre M Kiefer; Mehdi Hamadani; John F DiPersio; Mark R Litzow; Michael Craig; Mitchell E Horwitz; Andrew S Artz; Brian L McClune; Hugo F Fernandez; Hien Kim Duong; Hati Kobusingye; Mandi Proue; Rebecca J Drexler; Mary M Horowitz; Bronwen E Shaw; John P Miller; Sakura Hosoba; Edmund K Waller; Steven M Devine Journal: Blood Adv Date: 2019-03-26
Authors: Luke Maggs; Francesca Kinsella; Y L Tracey Chan; Suzy Eldershaw; Duncan Murray; Jane Nunnick; Joanne Bird; Charles Craddock; Jianmin Zuo; Ram Malladi; Paul Moss Journal: Blood Adv Date: 2017-08-21
Authors: Laura F Newell; Kelsea M Shoop; Rebekah J Knight; Sara N Murray; Rogelyn P Kwock; Carol E Jacoby; Susan Slater; Bryon E Allen; Casondra Ottowa; Brad Cota; Peggy L Appel; Rachel J Cook; Richard T Maziarz; Gabrielle Meyers Journal: Cytotherapy Date: 2019-05-10 Impact factor: 5.414
Authors: Ayman Saad; Lawrence Lamb; Tao Wang; Michael T Hemmer; Stephen Spellman; Daniel Couriel; Amin Alousi; Joseph Pidala; Hisham Abdel-Azim; Vaibhav Agrawal; Mahmoud Aljurf; Amer M Beitinjaneh; Vijaya Raj Bhatt; David Buchbinder; Michael Byrne; Jean-Yves Cahn; Mitchell Cairo; Paul Castillo; Saurabh Chhabra; Miguel Angel Diaz; Shatha Farhan; Yngvar Floisand; Hadar A Frangoul; Shahinaz M Gadalla; James Gajewski; Robert Peter Gale; Manish Gandhi; Usama Gergis; Betty Ky Hamilton; Peiman Hematti; Gerhard C Hildebrandt; Rammurti T Kamble; Abraham S Kanate; Pooja Khandelwal; Aleksandr Lazaryan; Margaret MacMillan; David I Marks; Rodrigo Martino; Parinda A Mehta; Taiga Nishihori; Richard F Olsson; Sagar S Patel; Muna Qayed; Hemalatha G Rangarajan; Ran Reshef; Olle Ringden; Bipin N Savani; Harry C Schouten; Kirk R Schultz; Sachiko Seo; Brian C Shaffer; Melhem Solh; Takanori Teshima; Alvaro Urbano-Ispizua; Leo F Verdonck; Ravi Vij; Edmund K Waller; Basem William; Baldeep Wirk; Jean A Yared; Lolie C Yu; Mukta Arora; Shahrukh Hashmi Journal: Biol Blood Marrow Transplant Date: 2019-05-11 Impact factor: 5.742
Authors: Clinton Yam; Lisa Crisalli; Selina M Luger; Alison W Loren; Elizabeth O Hexner; Noelle V Frey; James K Mangan; Amy Gao; Edward A Stadtmauer; David L Porter; Ran Reshef Journal: Am J Hematol Date: 2016-07-12 Impact factor: 10.047
Authors: Paul S Martin; Shuli Li; Sarah Nikiforow; Edwin P Alyea; Joseph H Antin; Philippe Armand; Corey S Cutler; Vincent T Ho; Natasha Kekre; John Koreth; C John Luckey; Jerome Ritz; Robert J Soiffer Journal: Haematologica Date: 2016-01-14 Impact factor: 9.941